藉此筹集所得款项总额最多约6.2亿港元(扣除开支前)(假设於记录日期或之前已发行股份数目概无变 动)。供股仅供合资格股东参与，而不合资格股东不得参与。倘获悉数认购，供股之估计所得款项净额 (经扣除所有必要开支)估计约为6.18亿港元。 格隆汇11月21日丨皇冠环球集团(00727.HK)公告，董事会建议，在满足若干条件的前提下，按于记录日 期每持有一(1)股股份获发三(3)股供股股份之基准，以每股供股股份0.65港元之认购价进行供股，较联 交所所报之收市价每股0.81港元折让约19.75%； ...

Core Viewpoint - Yongtai Bio-B (06978) has announced significant oversubscription in its rights issue, indicating strong investor interest and confidence in the company's future prospects [1][2] Group 1 - The company received valid acceptances for a total of 92.1758 million rights shares, representing approximately 89.56% of the total 103 million rights shares offered [1] - There were 8 valid applications for additional rights shares, totaling 446 million shares, which is about 433.15% of the total rights shares offered [1] - In total, there were 21 valid acceptances and applications for 538 million rights shares, amounting to approximately 522.71% of the total rights shares offered [1] Group 2 - A total of 435 million rights shares were oversubscribed, which is about 422.71% of the total 103 million rights shares offered [2] - The allocation of additional rights shares was made based on a ratio of approximately 2.41% of the number of additional shares applied for, due to insufficient shares to meet all valid applications [2] - There was no prioritization for applications based on existing shareholdings or for consolidating fractional shares into whole shares [2]

Group 1 - The company, Yu Neng Holdings (00442), announced a rights issue where eligible shareholders will receive 1 share for every 2 existing shares held, at a subscription price of HKD 0.710 per share [1] - The rights issue aims to raise a maximum net amount of approximately HKD 61 million by issuing up to 86.35 million shares, assuming no changes in the number of shares issued prior to the record date [1] - As of March 31, 2025, the company reported cash and bank balances of approximately HKD 36.3 million, indicating a cautious financial strategy to strengthen its financial position and support future business development through the rights issue [1]

Core Viewpoint - The recent stock transfer of Ying Sheng Science (00209) indicates a significant movement in shareholder interests, coinciding with the company's proposed rights issue to raise capital [1] Group 1: Stock Transfer - On November 7, Ying Sheng Science's shareholders transferred shares from Li Hing Stock to Yao Cai Securities, with a transfer market value of HKD 3.7566 million, accounting for 8.09% of the total shares [1] Group 2: Rights Issue - Ying Sheng Science announced a proposed rights issue, offering 7 new shares for every existing share held at a subscription price of HKD 0.14 per share [1] - The company aims to issue up to approximately 1.3 billion new shares, assuming no changes in the number of shares issued as of the record date, to raise a total of approximately HKD 182 million [1]

Core Viewpoint - The recent transfer of shares for Ying Sheng Science (00209) indicates a strategic move by shareholders, coinciding with the company's proposed rights issue to raise capital [1] Group 1: Shareholder Activity - On November 6, shareholders of Ying Sheng Science transferred shares from Futu Securities International Hong Kong to Wutong Securities, with a market value of HKD 8.1286 million, representing 14.35% of the total shares [1] Group 2: Company Announcement - Ying Sheng Science announced a rights issue proposal, offering 7 new shares for every existing share held at a subscription price of HKD 0.14 per share [1] - The company aims to issue up to approximately 1.3 billion new shares, assuming no changes in the number of shares issued as of the record date, to raise a total of approximately HKD 182 million [1]

Core Viewpoint - The recent transfer of shares for Ying Sheng Science (00209) indicates a strategic move by shareholders, with a significant portion of shares being moved to a different brokerage, potentially reflecting investor sentiment and market positioning [1] Group 1: Shareholder Activity - On November 6, shareholders of Ying Sheng Science transferred shares from Futu Securities International Hong Kong to Wutong Securities, with a total market value of HKD 8.1286 million, accounting for 14.35% of the company's shares [1] Group 2: Corporate Actions - Ying Sheng Science announced a proposed rights issue, offering 7 new shares for every existing share held at a subscription price of HKD 0.14 per share [1] - The company aims to raise a maximum of approximately HKD 182 million through the issuance of up to 1.3 billion rights shares, assuming no changes in the number of shares issued as of the record date [1]

Core Viewpoint - 惠陶集团 plans to issue up to 261 million shares through a rights issue at a subscription price of HKD 0.20 per share, aiming to raise approximately HKD 52.25 million before expenses [1] Group 1: Rights Issue Details - The rights issue will be based on a ratio of 3 new shares for every 1 share held by eligible shareholders on the record date [1] - The estimated net proceeds from the rights issue will be approximately HKD 49.44 million [1] - The subscription price represents a discount of about 6.98% compared to the last closing price of HKD 0.215 per share on the Stock Exchange [1] Group 2: Offering Structure - The rights issue will be conducted on a non-underwritten basis, meaning there will be no additional application arrangements for shareholders [1] - The rights issue will not be presented to excluded shareholders [1]

Core Points - Huatai UBS (08006) announced that as of October 13, 2025, it received a total of 33 valid applications for a rights issue, involving 93.7938 million shares, which represents approximately 42.4% of the total shares offered in the rights issue [1] - The rights issue was not fully subscribed, resulting in a shortfall of 128 million shares, accounting for about 57.6% of the total shares offered, which will be handled according to the compensation arrangement [1] - By the deadline of October 28, 2025, all 128 million unsubscribed shares and shares not sold by excluded shareholders were successfully placed at a price of HKD 0.08 per share, equivalent to the subscription price, leading to no net proceeds available for distribution to non-participating shareholders [1] - The total amount raised from the rights issue, including the placement, was approximately HKD 17.7 million, with a net amount of about HKD 16.6 million after expenses [1]

Group 1 - The company proposes a rights issue of up to 202 million shares at a subscription price of HKD 0.20 per share, aiming to raise a maximum of approximately HKD 40.4 million [1] - The subscription price represents a discount of about 9.09% compared to the closing price of HKD 0.22 on October 31, 2025 [1] - If fully subscribed, the estimated net proceeds from the rights issue, after expenses, will be approximately HKD 38 million, with plans to use around HKD 28 million for debt repayment and HKD 10 million for general working capital [1] Group 2 - The company will establish a compensation arrangement through the placement of unallocated rights shares to independent underwriters, benefiting shareholders who participate in the rights issue [2] - An independent board committee has been formed to provide opinions on the fairness and reasonableness of the terms of the rights issue and related transactions, ensuring alignment with the interests of the company and its shareholders [2] - An independent financial advisor has been appointed to advise the independent board committee and shareholders on how to vote regarding the rights issue [2]

Core Viewpoint - 嘉艺控股 proposes a rights issue to raise up to approximately HKD 40.4 million by issuing a maximum of 202 million shares at a subscription price of HKD 0.20 per share, which represents a discount of about 9.09% to the closing price on October 31, 2025 [1][2] Group 1 - The company plans to use approximately HKD 28 million of the net proceeds to repay debts and outstanding payables, and about HKD 1 million for general working capital [1] - The rights issue will not be underwritten and is only available to qualifying shareholders, with no arrangements for additional applications [1] - The estimated net proceeds from the rights issue, assuming full subscription, will be around HKD 38 million after deducting expenses [1] Group 2 - The company has established an independent board committee to consider the fairness and reasonableness of the terms of the rights issue and related transactions, providing advice to independent shareholders [2] - An independent financial advisor has been appointed to assist the independent board committee in evaluating the terms of the rights issue and advising on how independent shareholders should vote [2] - The company will arrange for the placement of unsubscribed rights shares through an independent placement agent to benefit shareholders [2]